Pub. Date : 2018
PMID : 30205729
9 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | HMGB1 represses the anti-cancer activity of sunitinib by governing TP53 autophagic degradation via its nucleus-to-cytoplasm transport. | Sunitinib | tumor protein p53 | Homo sapiens |
| 2 | Here we report that resistance to sunitinib therapy was driven by autophagic degradation of TP53/p53. | Sunitinib | tumor protein p53 | Homo sapiens |
| 3 | Here we report that resistance to sunitinib therapy was driven by autophagic degradation of TP53/p53. | Sunitinib | tumor protein p53 | Homo sapiens |
| 4 | Mechanistically, the transport of TP53 from the nucleus to the cytoplasm was essential for the sunitinib-induced autophagic degradation of TP53 and did not require TP53 nuclear export signals (NESs). | Sunitinib | tumor protein p53 | Homo sapiens |
| 5 | Mechanistically, the transport of TP53 from the nucleus to the cytoplasm was essential for the sunitinib-induced autophagic degradation of TP53 and did not require TP53 nuclear export signals (NESs). | Sunitinib | tumor protein p53 | Homo sapiens |
| 6 | Mechanistically, the transport of TP53 from the nucleus to the cytoplasm was essential for the sunitinib-induced autophagic degradation of TP53 and did not require TP53 nuclear export signals (NESs). | Sunitinib | tumor protein p53 | Homo sapiens |
| 7 | Importantly, sunitinib induced the degradation of all TP53 proteins, except for TP53 proteins with mutations in the interaction domain of TP53 with HMGB1 (amino acids 313 to 352). | Sunitinib | tumor protein p53 | Homo sapiens |
| 8 | In conclusion, our data identify an alternative HMGB1-mediated TP53 protein turnover mechanism that participates in the resistance of sunitinib and suggest HMGB1 as a potential therapeutic target for improving clinical outcomes of sunitinib. | Sunitinib | tumor protein p53 | Homo sapiens |
| 9 | In conclusion, our data identify an alternative HMGB1-mediated TP53 protein turnover mechanism that participates in the resistance of sunitinib and suggest HMGB1 as a potential therapeutic target for improving clinical outcomes of sunitinib. | Sunitinib | tumor protein p53 | Homo sapiens |